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Abstract
Background: Vaccinia virus strain Lister Elstree (VACV) is a test virus in the DVV/RKI guidelines as representative of the 
stable enveloped viruses. Since the potential risk of laboratory-acquired infections with VACV persists and since the 
adverse effects of vaccination with VACV are described, the replacement of VACV by the modified vaccinia Ankara 
strain (MVA) was studied by testing the activity of different chemical biocides in three German laboratories.
Methods: The inactivating properties of different chemical biocides (peracetic acid, aldehydes and alcohols) were 
tested in a quantitative suspension test according to the DVV/RKI guideline. All tests were performed with a protein 
load of 10% fetal calf serum with both viruses in parallel using different concentrations and contact times. Residual 
virus was determined by endpoint dilution method.
Results: The chemical biocides exhibited similar virucidal activity against VACV and MVA. In three cases intra-laboratory 
differences were determined between VACV and MVA - 40% (v/v) ethanol and 30% (v/v) isopropanol are more active 
against MVA, whereas MVA seems more stable than VACV when testing with 0.05% glutardialdehyde. Test accuracy 
across the three participating laboratories was high. Remarkably inter-laboratory differences in the reduction factor 
were only observed in two cases.
Conclusions: Our data provide valuable information for the replacement of VACV by MVA for testing chemical biocides 
and disinfectants. Because MVA does not replicate in humans this would eliminate the potential risk of inadvertent 
inoculation with vaccinia virus and disease in non-vaccinated laboratory workers.
Background
The global eradication of variola virus is one of the great-
est achievements of modern medicine. Following this
eradication, routine childhood vaccination against the
causative agent was halted because of a declining proba-
bility of the importation and spread and occasional seri-
ous side effects of the vaccination [1]. In Europe the
vaccinia virus strain Lister Elstree (VACV) was used [2].
Thereafter, for nearly three decades (1972 to 2003),
American laboratory workers were the only group put
forward for periodic smallpox vaccination. The Advisory
Committee on Immunization Practices (ACIP) recom-
mend a smallpox booster vaccination at least every 10
years for those employees who handle non-highly attenu-
ated vaccinia virus or other orthopoxviruses (e.g., mon-
keypox) [3].
Due to the incidence of serious side effects in immuno-
competent individuals (about 1/500,000) a more attenu-
ated vaccinia virus with a high safety profile for
mammalian species was developed - the so-called modi-
fied vaccinia Ankara strain (MVA) [4,5]. In the meantime
MVA is a widely used tool in molecular biology in labora-
tories around the world.
Presently the vaccinia virus Lister Elstree is still used as
model virus for testing the virucidal activity of chemical
disinfectants. In Europe the norm EN 14476:2007 exists
for determining virucidal activity [6]. This norm is only
designed to determine "complete virucidal activity" (i.e.
enveloped and non-enveloped viruses) which is not
needed in all cases, e.g. for inactivation of blood-borne
viruses. The number of active substances achieving viru-
cidal activity is limited. Taking into consideration com-
patibility and environmental implications, a German
national guideline [7] for human medicine permits addi-
tional tests where a disinfectant only has "limited viru-
cidal activity" (active against enveloped viruses such as
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HIV, HBV, and HCV) [8], which means that it has proven
activity against two representatives of enveloped viruses -
vaccinia virus and bovine viral diarrhea virus (BVDV).
Apart from this aspect, the consequence of the guideline
is that despite a growing number of humans without
immunity against vaccinia virus, VACV is still used in
laboratories to test the virucidal efficacy of chemical dis-
infectants. As model viruses for "non-enveloped" viruses
the guidelines of the German Association for the Control
of Virus Diseases (DVV) and the Robert Koch-Institute
(RKI) [7] prescribes poliovirus type 1 vaccine strain LSc-
2ab, adenovirus type 5 strain Adenoid 75 and polyomavi-
rus SV 40 strain 777.
In veterinary medicine vaccinia virus strain Lister
Elstr ee, ECBO-virus strain LCR -4, reovirus type 1 and
Newcastle-Disease-Virus strain Montana are required for
virucidal testing of chemical disinfectants, pursuant to
the guideline of the German Veterinary Medical Society
(DVG) [9].
The DVV/RKI guidelines state that laboratory workers
handling vaccinia virus should be vaccinated [7]. How-
ever, there are concerns about the adverse effects of vac-
cination with VACV. This objection has arisen as a result
of vaccinations against smallpox which have been per-
formed as a consequence of and as preventive measure
against putative bioterrorist attacks [10-12].
I n  t h e  U S A  i t  i s  n o t  n ec es s a ry  t o  r e po rt  la bo r a t o ry-
acquired VACV infections - nevertheless between 2005
and 2007, five cases were reported to the CDC [13].
These infections typically occurred in unvaccinated
workers [14] and could be associated with high inoculum
and inoculation routes with a high risk of complications
[15]. Additionally, in other parts of the world several
reports exist regarding inadvertent inoculation and labo-
ratory-acquired VACV infections [16-21].
Within this context it is important to highlight that in a
recently published study comparable results could be
shown when using MVA instead of vaccinia virus strain
Lister Elstree when testing chemical disinfectants for
virucidal activity. This study was conducted according to
the DVG guidelines with quantitative suspension and
qualitative carrier tests [21].
In order to investigate the possibility of substituting
VACV with MVA under the guidelines of the DVV/RKI,
different biocides (peracetic acid, aldehydes and alco-
hols), which are often ingredients used in disinfectants,
were tested with quantitative suspension tests using
VACV and MVA in parallel. The tests were performed in
the presence of organic load. Furthermore, the aim of the
study was to evaluate the robustness of the testing
method when performing an inter-laboratory compari-
son (as an external quality assurance programme (EQA)).
Therefore, the results of three laboratories were com-
pared using statistical analysis as required by the DVV/
RKI guidelines [7].
Methods
Participants in the external quality assurance program 
(EQA)
Three German laboratories participated in this EQA pro-
gram (a list of participants is given in the acknowledge-
ments section) - lab. 1, lab 2, lab. 3, respectively.
Participation was open and free of charge to all laborato-
ries.
Viruses and cell cultures
MVA (kindly provided by Prof. Dr. Truyen, Leipzig) were
propagated in BHK-21 (Baby hamster kidney cells, kindly
provided by Friedrich Löffler Institut, Insel Riems, Ger-
many) and VACV (ATCC VR-1549) in African green
monkey kidney cells (Vero, ATCC CRL-1586). For virus
Figure 2 Time-dependent virucidal activity of 0.1% glutardialde-
hyde against VACV and MVA (shown are exemplary values for 
one of the test laboratories). *After this contact time the measurable 
RF was limited by cytotoxic reactions and/or the amount of infectious 
viruses in the virus stock).
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Figure 1 Concentration-dependent virucidal activity of peracetic 
acid against VACV and MVA (shown are exemplary values for one 
of the test laboratories). *At this concentration the measurable RF 
was limited by cytotoxic reactions and/or the amount of infectious vi-
ruses in the virus stock).
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propagation cells were grown at 37°C and 5% CO2 in min-
imum essential medium (MEM) supplemented with 10%
foetal calf serum (FCS). These cells were infected with a
multiplicity of infection of 0.1. After cells exhibited a
cytopathic effect, they were subjected to a twofold freeze/
thaw procedure followed by a low speed centrifugation
(10 min and 1000 × g) in order to sediment cell debris.
After aliquoting, test virus suspension was stored at -
80°C.
Biocides
Five biocides were used in the study: formaldehyde (0.7%,
w/v; pH 7; contact time: 5, 15, 30, 60 min), glutardialde-
hyde (0.05, 0.1, 0.5%, w/w; pH 8.4; contact time: 0.5, 2, 5
min), ethanol (30, 40, 50, 60%, v/v; contact time: 1, 2 min),
isopropanol (20, 30, 40, 50, 60%, v/v; contact period: 1, 2
min), and peracetic acid (PAA) (0.001, 0.0025, 0.005, 0.01,
0.05, 0.1%, v/v; contact time: 1, 2 min). The pH values of
the biocides were measured if necessary.
Preparation of test samples
Test samples for the proficiency panel (stock solutions)
were generated by an independent provider (kindly pro-
vided by Dr. von Rheinbaben, Ecolab Deutschland
GmbH, Düsseldorf, Germany). All samples were sent out
by a commercial parcel service and arrived within 24 h of
dispatch, according to the date of receipt provided by the
participants. The participants were asked to analyze the
material according to the method described in the Ger-
man DVV/RKI guidelines [7].
Determination of cytotoxicity
In order to determine cytotoxicity biocides were serially
diluted tenfold in MEM up to a dilution of 10-8. One part
by volume of water of standardized hardness (instead of
virus suspension) was mixed with one part by volume of
organic load and eight parts by volume of the biocide.
Aliquots of 50-100 μl from each test concentration and
each dilution was then inoculated into seven to eight
wells of a 96-well microtitre plate containing 50 μl cell
suspension of Vero or BHK-21 cells, respectively. The cell
cultures were observed for cytotoxic effects for the same
incubation time as afterwards used for the suspension
tests.
Quantitative suspension tests
Tests were carried out in accordance with the DVV/RKI
guidelines at 20°C [7]. One part by volume of virus sus-
pension (titre of at least 107-108 tissue culture infectious
dosis 50% (TCID50)/ml) and one part by volume of the
organic load were mixed with eight parts by volume of
the biocide. The tests were carried out in ambient tem-
peratures of 20-22°C. Infectivity was determined by
means of end point dilution titration in microtitre plates.
At the end of the chosen exposure time, activity of the
biocides was immediately stopped by serial dilutions with
ice-cold cell culture medium. 50 μl from each dilution
were placed in seven to eight wells of a sterile polystyrene
flat-bottomed 96-well microtitre plate containing 50 μl
cell suspension (10-15 × 103 cells per well) of Vero or
BHK-21 cells. Cultures were observed for cytopathic
effects (CPE) after seven to ten days of inoculation. All
tests were conducted in two independent tests run on dif-
ferent days. Virus controls were incorporated after the
longest exposure time. All tests were performed with an
organic load of 10% FCS.
Statistical analysis
The virus titres were determined using the method of
Spearman and Kaerber [22,23] and expressed as TCID50/
Figure 3 Time-dependent virucidal activity of 0.7% formalde-
hyde against VACV tested in all 3 laboratories. *After this contact 
time the measurable RF in at least one of the laboratories was limited 
by cytotoxic reactions and/or the amount of infectious viruses in the 
virus stock.
0
1
2
3
4
5
5 15* 30* 60*
contact time (min)
V
i
r
u
s
 
R
F
 
(
l
o
g
 
1
0
)
Lab # 1
Lab # 2
Lab # 3
Figure 4 Concentration-dependent virucidal activity of isopropa-
nol against MVA tested in all 3 laboratories (the minor absolute 
RF of Lab 3 is related to the lower starting virus titre). *At this con-
centration the measurable RF was limited by cytotoxic reactions and/
or the amount of infectious viruses in the virus stock.
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ml including standard deviation. Titre reduction is pre-
sented as the difference between the virus titre after con-
tact time with the substance and control virus titre. This
difference is given as reduction factor (RF) including its
95% confidence interval (CI). A reduction of infectivity of
≥4 log10 steps (inactivation ≥99.99%) was regarded as evi-
dence of sufficient virucidal activity. The calculation was
performed according to the DVV/RKI guidelines [7]. Bio-
logically relevant RF differences between viruses or labo-
ratories were defined as ≥1 log10 step considering the
lower respectively upper bounds of the 95% CI.
Results
The test concentrations and contact periods were chosen
in order to observe a kinetic and the transition from non-
efficient to efficient virus inactivation. For ethanol a con-
centration-dependent virucidal activity was seen for
VACV as well as for MVA. At concentrations ≥50% (v/v) a
Table 1: Virucidal activity of ethanol, isopropanol and peracetic acid (PAA) against VACV depending on concentration and 
contact time
VACV reduction factor (RF) (log10)
biocide results lab 1 results lab 2 results lab 3
1 min 1 min 1 min
30% ethanol 0.13 ± 0.38 -0.25 ± 0.33 ≥0.14 ± 0.60
40% ethanol 2.26 ± 0.36 2.69 ± 0.54 3.86 ± 0.48
50% ethanol ≥4.38 ± 0.37 ≥5.94 ± 0.31 ≥5.0 ± 0.40
60% ethanol ≥4.38 ± 0.37 ≥5.94 ± 0.31 ≥5.0 ± 0.40
20% isopropanol 0.82 ± 0.27 0.00 ± 0.52 -0.57 ± 0.45
30% isopropanol 0.32 ± 0.34 1.87 ± 0.25 1.86 ± 0.48
40% isopropanol ≥4.38 ± 0.37 ≥5.94 ± 0.31 ≥5.0 ± 0.40
50% isopropanol ≥4.38 ± 0.37 ≥5.94 ± 0.31 ≥5.0 ± 0.40
60% isopropanol ≥4.38 ± 0.37 ≥5.94 ± 0.31 ≥5.0 ± 0.40
0.001% PAA 0.94 ± 0.41 0.56 ± 0.48 0.71 ± 0.53
0.0025% PAA 3.38 ± 0.52 n.d. n.d.
0.005% PAA ≥4.50 ± 0.38 n.d. n.d.
0.01% PAA ≥3.50 ± 0.38 ≥5.94 ± 0.31 ≥4.0 ± 0.40
0.05% PAA ≥3.50 ± 0.38 ≥4.94 ± 0.31 ≥4.0 ± 0.40
0.1% PAA ≥4.57 ± 0.41 ≥6.38 ± 0.37 ≥3.86 ± 0.39
The prefix "≥" indicates that the determination of the RF is limited by cytotoxic reactions and/or the amount of infectious viruses in the test 
virus suspension
n.d. = not doneRabenau et al. BMC Infectious Diseases 2010, 10:185
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maximum titre reduction of at least 103.6 TCID50/ml was
observed after 1 min with both - VACV (Table 1) and
MVA (Table 2). Testing a concentration of 40% (v/v) in all
three laboratories residual infectivity could be detected
after one or two minutes. A complete inactivation of
VACV and MVA was also detected for isopropanol and
PAA at concentrations of ≥40% (v/v) and 0.01%, respec-
tively (Table 1, 2). At lower concentration levels intra-lab-
oratory heterogeneous discrepancies between VACV and
MVA could be seen (Figure 1). Furthermore, in some
cases inter-laboratory discrepancies were obvious for the
same virus.
A time-dependent increase of virucidal activity of the
biocides was detected when testing lower concentrations
(not shown in table). Concerning glutardialdehyde a time
- and concentration-dependent increase of virucidal
activity were detectable for the 0.1% and 0.05% concen-
trations for both viruses (Table 3, Figure 2). In contrast,
for formaldehyde a time-dependent RF increase could be
seen only for VACV (Figure 3), whilst the maximal mea-
Table 2: Virucidal activity of ethanol, isopropanol and peracetic acid (PAA) against MVA depending on concentration and 
contact time
MVA reduction factor (RF) (log10)
biocide results lab 1 results lab 2 results lab 3
1 min 1 min 1 min
30% ethanol -0.10 ± 0.37 -0.06 ± 0.51 -0.14 ± 0.62
40% ethanol 2.80 ± 0. 53 ≥5.32 ± 0.38 1.71 ± 0.60
50% ethanol ≥5.40 ± 0.36 ≥5.32 ± 0.38 ≥3.57 ± 0.40
60% ethanol ≥5.40 ± 0.36 ≥5.32 ± 0.38 ≥3.57 ± 0.40
20% isopropanol 0.06 ± 0.37 -0.44 ± 0.63 0.42 ± 0.46
30% isopropanol 0.50 ± 0.44 3.69 ± 0.53 0.71 ± 0.60
40% isopropanol ≥5.40 ± 0.36 ≥5.32 ± 0.38 ≥3.57 ± 0.40
50% isopropanol ≥5.40 ± 0.36 ≥5.32 ± 0.38 ≥3.57 ± 0.40
60% isopropanol ≥5.40 ± 0.36 ≥5.32 ± 0.38 ≥3.57 ± 0.40
0.001% PAA 0.90 ± 0.47 0.19 ± 0.56 1.14 ± 0.56
0.0025% PAA 4.75 ± 0.31 n.d. n.d.
0.005% PAA ≥5.66 ± 0.47 n.d. n.d.
0.01% PAA ≥5.66 ± 0.47 ≥5.32 ± 0.38 ≥3.57 ± 0.56
0.05% PAA ≥4.60 ± 0.47 ≥4.32 ± 0.38 ≥4.14 ± 0.40
0.1% PAA ≥3.94 ± 0.47 ≥5.19 ± 0.43 ≥4.14 ± 0.40
The prefix "≥" indicates that the determination of the RF is limited by cytotoxic reactions and/or the amount of infectious viruses in the test 
virus suspension
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Table 3: Virucidal activity of glutardialdehyde against VACV and MVA virus depending on concentration and contact time
VACV RF (log10)
Biocide results lab 1 results lab 2 results lab 3
0.5 min 2 min 5 min 0.5 min 2 min 5 min 0.5 min 2 min 5 min
0.05% glutardialdehyde 0.50 ± 0.34 4.06 ± 0.32 ≥4.82 ± 0.29 0.50 ± 0.44 3.88 ± 0.53 ≥5.38 ± 0.37 ≥3.86 ± 0.49 ≥4.43 ± 0.49 ≥4.58 ± 0.49
0.1% glutardialdehyde 2.75 ± 0.39 ≥3.82 ± 0.29 ≥3.82 ± 0.29 2.13 ± 0.49 ≥5.38 ± 0.37 ≥5.38 ± 0.37 ≥3.86 ± 0.39 ≥3.86 ± 0.39 ≥3.86 ± 0.39
0.5% glutardialdehyde ≥2.82 ± 0.29 ≥2.82 ± 0.29 ≥2.82 ± 0.29 ≥5.38 ± 0.37 ≥5.38 ± 0.37 ≥5.38 ± 0.37 ≥4.0 ± 0.35 ≥4.0 ± 0.35 ≥4.0 ± 0.35
MVA RF (log10)
Biocide results lab 1 results lab 2 results lab 3
0.5 min 2 min 5 min 0.5 min 2 min 5 min 0.5 min 2 min 5 min
0.05% glutardialdehyde 1.38 ± 0.41 ≥3.88 ± 0.42 ≥4.50 ± 0.38 0.19 ± 0.56 2.07 ± 0.48 ≥4.19 ± 0.43 1.86 ± 0.53 ≥3.14 ± 0.40 ≥3.14 ± 0.40
0.1% glutardialdehyde 2.81 ± 0.38 ≥4.00 ± 0.38 ≥4.00 ± 0.38 0.69 ± 0.51 ≥4.32 ± 0.35 ≥4.32 ± 0.35 ≥3.14 ± 0.40 ≥3.14 ± 0.40 ≥3.14 ± 0.40
0.5% glutardialdehyde ≥3.50 ± 0.38 ≥3.50 ± 0.38 ≥3.50 ± 0.38 ≥3.32 ± 0.35 ≥3.32 ± 0.35 ≥3.32 ± 0.35 ≥3.14 ± 0.40 ≥3.14 ± 0.40 ≥3.14 ± 0.40
The prefix "≥" indicates that the determination of the RF is limited by cytotoxic reactions and/or the amountRabenau et al. BMC Infectious Diseases 2010, 10:185
http://www.biomedcentral.com/1471-2334/10/185
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surable RF for MVA was already apparent after the short-
est incubation period of 5 min (data not shown).
The standard deviations for the control virus titrations
were below 0.5 log10 TCID50/ml (not shown in tables).
In many cases the RF is marked with the prefix "≥" indi-
cating that the determination of the RF was limited by
cytotoxic reactions and/or the amount of infectious
viruses in the virus stock. Furthermore, the different lev-
els on test virus suspension are to some extent responsi-
ble for inter-laboratory and inter-virus RF differences.
For the different biocides all RF data were compared
with regard to relevant intra- and inter-laboratory differ-
ences of viable VACV and MVA. In two cases remarkable
inter-laboratory RF differences (≥1 log10 step considering
95% CI) were seen. The different results concerned in
both cases MVA (for 40% ethanol and 30% isopropanol)
(Figure 4). Furthermore, in three cases intra-laboratory
differences were demonstrated between VACV and MVA
(for 40% ethanol, 30% isopropanol, 0.05% glutardialde-
hyde) (Tables 1, 2, 3).
Discussion
VACV is still used in many laboratories - e.g. as a model
virus for a large enveloped DNA virus. The virus is also
required in the German guidelines of DVV/RKI and DVG
as a model virus for testing the virucidal efficacy of chem-
ical disinfectants [7,9].
Before eradication of variola the risk of human labora-
tory infection with VACV was negligible because most of
the population was vaccinated with VACV [24]. As a
long-term consequence of the smallpox eradication the
number of people with a sufficient immunity has
decreased. This trend is higher in younger laboratory
workers where no orthopox basic immunity exists and
the potential risk of laboratory-acquired infections per-
sists [13,14,16-20].
To diminish this risk one possibility would be to vacci-
nate these laboratory workers, but there are concerns
about the adverse effects of vaccination with VACV
because such side effects are about 10 times more com-
mon in primary vaccinees than in those who are revacci-
nated [25]. Therefore, it would be worthwhile to
substitute VACV with MVA.
The present study was undertaken with two aims in
mind: first to evaluate a possible substitution of VACV
with MVA and second to investigate the robustness of the
test in evaluating the laboratory proficiency in a multi-
center study. Three different laboratories participated in
this EQA.
By testing five chemical biocides from different groups
(peracetic acid, aldehydes, and alcohols) in a quantitative
suspension test [7] we were able to show that they exhib-
ited similar virucidal activity against VACV and MVA or -
put differently - that both viruses revealed comparable
stability and susceptibility to the tested biocides. This
data confirms the results from Hartnack et al. [21], who
achieved similar results testing four different DVG-listed
commercially available chemical disinfectants represent-
ing different groups of chemicals in quantitative suspen-
sion tests and qualitative carrier tests with poplar wood
and gauze. The high and very similar viability of VACV
and MVA had been previously confirmed in different
studies [26-29].
In our study we chose the concentration of the biocides
and the length of the exposure time in order to see a
kinetic and the transition from non-efficient to efficient
virus inactivation. For the different biocides all RF data
were compared with regard to relevant (≥1 log10 step con-
sidering 95% CI) intra- and inter-laboratory differences of
viable VACV and MVA. Marked inter-laboratory RF dif-
ferences were only observed in two cases; in three cases
intra-laboratory differences between VACV and MVA
were demonstrated.
Overall MVA appears to have a similar stability as
VACV, but in some cases it seems to be more fragile (e.g.
at 40% ethanol and 30% isopropanol). In contrast, when
testing with 0.05% glutardialdehyde, MVA seems to be
more stable than VACV. One reason for these differences
could be that in the selection of concentration and con-
tact time-relation the kinetic was in the ascending pro-
portion of the sigmoid area of the inactivation curve.
These conditions were chosen in order to see a kinetic
and the transition from non-efficient to efficient virus
inactivation. On the other hand this would mean that
even the slightest change in conditions or the test proce-
dure could cause a maximum variance and lead to mea-
surable changes in the results. Therefore, the RF
variations do not appear to be attributable to relevant dif-
ferences in the tenacity of both viruses. Furthermore, dif-
ferences in the tenacity of both viruses are only found at
concentrations far below the standards applied in prac-
tice.
This is the first multi-center German EQA study on
testing the virucidal activity of chemical biocides accord-
ing to the DVV/RKI guidelines. Comparative testing of
defined samples is the most efficient method to identify
weaknesses in a laboratory or in certain methodological
components. Our data shows that the test accuracy
across the three participating laboratories is high. In all
cases the standard deviations for the control virus titra-
tions were below 0.5 log10 TCID50/ml. Observed RF dis-
crepancies are found at a concentration of low activity
and might be caused by different preparation of the virus
test suspension, usage of different cell lines (Vero or
BHK-21 cells), limitations by cytotoxic reactions and the
aforementioned strong influence of experimental condi-
tions due to the inactivation kinetic.Rabenau et al. BMC Infectious Diseases 2010, 10:185
http://www.biomedcentral.com/1471-2334/10/185
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Conclusion
As stated by Hartnack et al. [21] our data confirms and
underlines that MVA could substitute VACV in the
chemical disinfectant testing guidelines [7,9]. Because
MVA does not replicate in humans this would eliminate
the potential risk of inadvertent inoculation with vaccinia
virus and disease in non-vaccinated laboratory workers.
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